The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole

British Journal of Clinical Pharmacology

Volumn 42, Issue 3, 1996, Pages 347-353

  Gill, Helen J ^a   Maggs, James L ^a   Madden, Stephen ^a   Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Fluconazole; Inhibition; Ketoconazole; Sulphamethoxazole hydroxylamine; Toxicity metabolism

Indexed keywords

COTRIMOXAZOLE; CYTOCHROME P450; DRUG METABOLITE; FLUCONAZOLE; KETOCONAZOLE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029836423     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.40110.x     Document Type: Article

References (47)

1. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992; 5: 1237-1257.
2. Keisu M, Ekman E, Wiholm B-E. Comparing risk estimates of sulfonamide-induced agranulocytosis from the Swedish Drug Monitoring System and a case-control study. Eur J Clin Pharmacol 1992; 43: 211-214.
3. Jung AC, Paauw DS. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 1994; 154: 2402-2406.
4. Hoover DR, Sahh A, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993; 329: 1922-1926.
5. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495-499.
6. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalised patients. Rev Infect Dis 1982; 4: 426-428.
7. Carr A, Tindall B, Penny R, Cooper DA. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993; 94: 21-25.
8. Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 1988; 244: 724-728.
9. Rieder MJ, Krause R, Bird IA, Dekaban GA. Toxicity of sulfonamide reactive metabolites in HIV-infected, HTLV-infected and non-infected cells. J Acq Im Defie Synd Hum Retrovirol 1995; 8: 134-140.
10. Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: Identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994; 94: 1017-1024.
11. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529-535.
12. Tingle MD, Coleman MD, Park BK. The effects of preincubation with cimetidine on the N-hydroxylation of dapsone by human liver microsomes. Br J Clin Pharmacol 1991; 32: 120-123.
13. Coleman MD, Scott AK, Breckenridge AM, Park BK. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 1990; 30: 761-767.
14. Coleman MD, Rhodes LE, Scott AK, et al. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis. Br J Clin Pharmacol 1992; 34: 244-249.
15. Rhodes LE, Tingle MD, Park BK, Chu P, Verbov JL, Friedmann PS. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol 1995; 132: 257-262.
16. May DG, Naukam RJ, Kambam JR, Branch RA. Cimetidine-carbaryl interaction in humans: Evidence for an active metabolite of carbaryl. J Pharmacol Exp Ther 1992; 292:1057-1061.
17. 4-Hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P450 2C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23: 406-414.
18. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
19. Back DJ, Tjia JF. Comparative effects of the anti-mycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporine by human liver microsomes. Br J Clin Pharmacol 1991; 32: 624-626.
20. Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol 1992; 34: 75-78.
21. Blum RA, Wilton JH, Hilligoss DM. et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-425.
22. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125-130.
23. Baciewicz AM, Baciewicz FA. Ketoconazole and fluconazole drug interactions. Arch Intern Med 1993; 153: 1970-1976.
24. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver. Identification of a cytochrome P450III gene family as the major cyclosporine-metabolising enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-635.
25. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolised to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522-526.
26. Gill HJ, Tingle MD, Park BK. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995; 40: 531-538.
27. 1-glucuronide conjugates in healthy human volunteers. Clin Drug Invest 1995; 9: 43-53.
28. Hargreaves JA, Jezequel S, Houston JB. Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 1994; 38: 175P.
29. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther 1986; 39: 654-659.
30. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-1518.
31. Dupont B, Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol 1988; 26: 67-71.
32. Koopmans PP, van der Ven AJAM, Vree TB, van der Meer JWM. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: Allergic or toxic. AIDS 1995; 9: 217-222.
33. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 2089-2098.
34. Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P450 2C9; An approach using designed trienilic acid derivatives and molecular modelling. Biochemistry 1995; 34: 10365-10375.
35. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochrome P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-758.
36. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.
37. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 13-34.
38. Arredondo G, Martinezjorda R, Calvo R, Aguirre C, Suarez E. Protein-binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther 1994; 32: 361-364.
39. Daneshmend TK, Warnock DW, Turner A, Roberts CJC. Pharmacokinetics of ketoconazole in normal subjects. J Antimicrobial Chem 1981; 8: 299-304.
40. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990; 12: S327-S333.
41. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in vitro 'rechallenge' with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286-289.
42. Cribb AE, Nuss CE, Alberts DW, et al Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 1996; 9: 500-507.
43. Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Drug Metab Dispos 1991; 19: 900-906.
44. Rieder MJ, Krause R, Bird IA. Time-course of toxicity of reactive sulfonamide metabolites. Toxicology 1995; 95: 141-146.
45. Coleman MD, Breckenridge AM, Park BK. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol 1989; 28: 389-395.
46. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochrome P-450 by cimetidine. Gastroenterology 1991; 101: 1680-1691.
47. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991; 51: 365-370.